上海齐鲁锐格医药研发有限公司 Shanghai Qiluruge Pharmaceutical Research And Development Co. Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics 2025-03-24 22:30
Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity 2025-01-11 01:30
Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer 2024-09-30 13:00
Regor to Present at the Goldman Sachs 45th Annual Global Healthcare Conference 2024-06-05 23:36
Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity 2024-03-08 23:24
Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy 2023-12-08 07:39
Regor Therapeutics Announces Completion of $90 Million Series B Financing 2021-02-19 08:00
1